hVIVO (LON:HVO) Stock Price Crosses Above 50 Day Moving Average – Here’s What Happened

hVIVO plc (LON:HVO)’s stock price passed above its 50-day moving average during trading on Thursday . The stock has a 50-day moving average of GBX 6.01 and traded as high as GBX 6.20. hVIVO shares last traded at GBX 6.09, with a volume of 6,746,193 shares trading hands.

Analysts Set New Price Targets

Several equities analysts have issued reports on the company. Peel Hunt reiterated an “add” rating and set a GBX 10 target price on shares of hVIVO in a research report on Thursday, November 20th. Shore Capital reaffirmed a “buy” rating and set a GBX 25 price objective on shares of hVIVO in a report on Thursday, January 29th. Two analysts have rated the stock with a Buy rating, According to MarketBeat, the stock has a consensus rating of “Buy” and an average price target of GBX 17.50.

hVIVO Stock Up 1.7%

The company has a market cap of £41.92 million, a PE ratio of 7.92 and a beta of 0.97. The firm has a 50-day simple moving average of GBX 6.01 and a two-hundred day simple moving average of GBX 7.55. The company has a debt-to-equity ratio of 33.86, a current ratio of 1.61 and a quick ratio of 1.16.

Insider Buying and Selling

In related news, insider Yamin Mo’ Khan acquired 3,310,405 shares of the company’s stock in a transaction dated Monday, December 15th. The stock was bought at an average price of GBX 6 per share, with a total value of £198,624.30. Also, insider Stephen Pinkerton bought 520,000 shares of the firm’s stock in a transaction that occurred on Monday, December 15th. The stock was bought at an average cost of GBX 6 per share, for a total transaction of £31,200. 5.25% of the stock is currently owned by company insiders.

About hVIVO

hVIVO plc operates as a pharmaceutical service and contract research company. The company is involved in testing vaccines and antivirals using human challenge clinical trials. It provides services to big pharma, biotech, government, and public health organizations. The company has a portfolio of human challenge study models for conditions, such as RSV, flu, human rhinovirus, asthma, malaria, cough, and COPD, as well as developing COVID-19 human challenge study model. In addition, the company is developing a database of infectious disease progression data that include Disease in Motion platform, which comprises unique datasets, such as clinical, immunological, virological, and digital (wearable) biomarkers.